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EDITORIAL

Eminence-Based Medicine: The King is Dead

A

lthough possibly difficult to reconcile, many of us nephrologists were trained in our discipline by what
some would refer to as ‘‘eminence-based medicine.’’ Our
supervising physicians were emperors of the courts of
medical knowledge and progress, often trained in basic
science and with evident knowledge of the Bonferroni correction to preclude cumulative type 1 errors or alpha inflation.1 These kings could, when they deigned to, humble
and stupefy us with their brilliance, solely steeped in the
faith of the mechanistic world of biological plausibility,
renal transport mechanisms, and pure, unconfounded,
unadulterated experimentation. Because ‘‘they said so,’’
they were correct and our own hypotheses were cast aside,
albeit as type 2 errors! Often and years later, we have come
to realize that the evidence for their decrees were simply
their best estimates based on either small, uncontrolled,
observational studies, sometimes ‘‘N’’ equaling ‘‘1,’’ or
simply a dearth of information. No lie was intended, just
an eliding of the facts whenever they existed.
All of this was supposed to have changed after the
genesis of evidence-based medicine and the dawn of critical appraisal methods to determine the weight and
goodness-of-fit of studies. However, we have been more
than slow to change. In fact, nephrologists represent
a group that almost defies the results of evidence-based
medicine. Blame has been cast on our discipline for its relative lack of randomized controlled trials. Moreover, even
when properly executed, the results of such trials are often ignored. The appearance of guidelines, based on evidence where feasible, and informed opinion when not,
has been demonized as weapons of insurers, payers,
and the government. Guideline committees that have
toiled assiduously over thousands of pages of disparate
and inhomogeneously constructed literature have consequently been treated like Dr. Stockmann in Ibsen’s ‘‘An
Enemy of the People.’’2
Why is the discipline of nephrology so far behind in its
adaptation to an evidence-based practice? One reason is
that there are relatively few large, randomized controlled
trials compared with per se the discipline cardiology,

which began its embrace of evidence more than 2 decades
ahead of nephrology. As a corollary, such trials are highly
expensive, and single endpoint measurements rather
than composite ones are difficult to attain in the realm
of the kidney. Truly, the complex nature of CKD patients,
particularly those suffering with ESRD, represents a degree of confounding that is absent from many other internal medicine specialties, but such an excuse can only be
used so many times. A second reason is that nephrology
has been so immersed in basic science that there was little
or no incentive to pursue funding of appropriate clinical
trials or practicing evidence-based medicine. A third is
that nephrologists have too long depended on observational studies. A fourth reason is that the bulk of larger
studies have been subject to bias, namely, pharmaceutical
studies that depend on multiple small sites for data accrual where training in qualified data acquisition is heterogeneous. Multiple other reasons exist and do not
require repetition or retrenchment.
However, randomized controlled trials cannot always
be conducted, possibly for technical or ethical reasons,
and one must then use established hierarchical rules of
engagement to determine quality of evidence. This hierarchy exists and represents a roadmap toward a better
conclusion to a question that may not have definitive answer. In such circumstances, well-conducted case-control
studies may provide meaningful estimates of exposure
and establish risk levels. Also, observational studies
may be informative when confounding and bias are
reduced—these cannot be completely eliminated. Overall, when there is doubt, the reduction of uncertainty begins with thoughtful weighing of evidence. We should
not dismiss that there are other considerations to contemplate in today’s ‘‘modern medicine,’’ including the
atavistic-sounding patient-centric approach and the use
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of comparative effectiveness research to guide therapy.
The founders of evidence-based medicine, as physicians,
comprehended this from the start and appreciated that
an evidence foundation is just one component of an
evidence-based, patient-centered, decision-making process. There was no intent to eradicate the art of medicine,
but to amplify it.
Comparative effectiveness research involves 7 steps:
Identification of new and emerging clinical interventions;
review and synthesis of current medical research; identification of gaps between existing medical research and
the needs of clinical practice; promotion and generation
of new scientific evidence and analytic tools; training
and development of clinical researchers; translation and
dissemination of research findings to diverse stakeholders; and reaching out to stakeholders via a citizens’
forum.3 Notably, comparative effectiveness research
does not preclude evidence-based medicine, but it does
not solely subscribe to it either. Goldenberg appeals, in
part, to this concept and reminds us to remain circumspect with her challenge: ‘‘The appeal to the authority
of evidence that characterizes evidence-based practices
does not increase objectivity but rather obscures the subjective elements that inescapably enter all forms of human
inquiry. The seeming common sense of EBM only occurs
because of its assumed removal from the social context of
medical practice. In the current age where the institutional power of medicine is suspect, a model that represents biomedicine as politically disinterested or merely
scientific should give pause.’’4 Nevertheless, adherence
to an evidence base can promote change and the remarkable achievement of core benchmarks in nephrology
CKD clinics, despite the ultimate question: ‘‘What are
the benchmarks?’’5
Therefore, we must educate and enrich our charges, our
colleagues, and most importantly, ourselves, in evidencebased medicine, not eminence-based medicine. Such education will only provide for patients in a more meaningful
way, prevent waste, and reduce the overall cost of health
care. This form of education does not supersede or better

others such as the basic sciences, but like them, it is
necessary and not sufficient. Evidence-based medicine
teaching must be plied early on and considered a fundamental competency in the same manner that the physical
examination was and still is. A true embracing of this proposal is challenging and requires a fundamental shift in
medical education. As a case in point, the Canadian medical school system zealously adopted and implemented
this attitude years ago. Future teachers must be taught
today, and curricula must be recast and exacted for successful learning of evidence-based medicine principles,
as espoused and advocated for by the Guest Editors,
Molony and Samuels, of this first-of-its-kind issue of Advances in Chronic Kidney Disease. The topics in this issue
should be considered pretext, not text, as the concepts
contained herein represent the first filter and lens through
which we more precisely partition and focus our clinical
decision making. This paradigm shift requires further
acknowledgment by medical societies and promotion because, despite this rallying cry, momentum for this effort
requires not only mass but velocity. Authority once had its
privileges but is no longer ensconced as the touchstone of
clinical medicine. The king is dead, and now we must act,
liberated from the tyranny of instinct and nonsystematic
applications of our own knowledge.
Jerry Yee, MD
Editor
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